Google DeepMind Launches AlphaGenome 2 for DNA Variant Prediction

Google DeepMind announced the launch of AlphaGenome 2 on November 11, 2026, introducing an AI model built to predict how DNA sequences and genetic variants affect specific human cell types and states. The model was trained on more than 100 million single-cell profiles across 68 tissues, marking a step forward in genetic research. It offers researchers a way to see the cellular mechanisms behind various diseases, which may lead to more precise therapies and treatments in the future.

Scientists have long struggled to link DNA variations to gene expression across different cell types. While earlier models like the original AlphaGenome could predict variant effects across broad tissue categories, they often missed the subtle differences found at the cellular level. AlphaGenome 2 changes this by allowing researchers to focus on specific cell types and conditions, providing a clearer picture of how genetic variants influence human health.

The development of AlphaGenome 2 involved a redesign of the model's architecture by researchers and engineers at Google DeepMind. By moving away from a broad tissue model toward a conditional approach, the system can now predict variant effects in disease-relevant cells that were once overlooked. This shift improves the model’s accuracy and creates new opportunities for studying personalized medicine and identifying rare diseases.

There are broader implications for healthcare as well. A better understanding of how DNA variants contribute to disease can lead to more effective medical interventions, potentially lowering healthcare costs and improving patient outcomes. As researchers learn more about genetic contributions to various conditions, they can work toward drug developments and therapeutic strategies tailored to individual patients, supporting a more personalized approach to medicine.

Looking forward, AlphaGenome 2 is expected to see further enhancements and new applications in genetic research. Currently, the model is available for non-commercial use through the AlphaGenome API, while commercial applications are being offered in private preview. As the scientific community begins to work with this tool, the likelihood of new discoveries in human genetics grows, highlighting the role of AI in understanding the complexities of the human genome.